1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc.

ALSE
Alseres Pharmaceuticals, Inc.US flagOther OTC
0.01
USD
+0.01
- -
398,255.00Market Cap
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
86.62
77.32
77.32
Basic EPS, GAAP
-12,367.41
-12,296.58
-9,097.28
-8,632.03
-5,174.48
-7,974.35
-5,179.74
-4,992.21
-2,306.71
96.01
-486.45
-268.56
-153.67
-126.76
Free Cash Flow per Basic Share
-11,554.01
-10,961.63
-6,440.7
-7,123.04
-4,527.29
-4,805.51
-6,481.24
-3,622.21
-1,725.24
-552.87
-419.78
-155.45
-275.33
-219.4
Dividend per Share
- -
- -
- -
148.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-90,261.86
-95,977.89
-77,107.19
-77,687.94
-49,548.29
-43,369.98
-43,148.94
-43,985.95
-41,614.45
-36,330.9
-33,205.35
-32,379.17
-32,532.84
-32,639.42
Tangible Book Value per Share
11,607.76
3,157.55
5,840.17
-2,157.91
3,342.36
-5,014.19
-5,939.18
-9,581.74
-10,168.95
-8,860.09
-5,164.93
-4,361.17
-1,739.81
-1,857.26
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-228.4
-119.21
-178.11
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-10
-11
-8
-11
-12
-26
-20
-21
-11
1
-3
-2
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-310.05
-198.75
-163.94
Working Capital
9
6
10
- -
7
-17
1
-5
-43
-42
-30
-9
-1
-2
LT Debt
- -
4
4
- -
- -
- -
24
34
- -
- -
- -
16
8
8
Total Equity
10
3
12
1
8
-17
-22
-40
-48
-47
-30
-26
-10
-11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.04
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'13
Mar'14
Jun'14
ST Debt
- -
- -
- -
LT Borrowings
8
8
8
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Dec'13
Mar'14
Jun'14
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
90.38%
-18.34%
-61.03%
Free Cash Flow
-1.24%
-22.08%
77.11%
Net Income, GAAP
-75.46%
-180.24%
-42.78%
Sales/Revenue/Turnover
- -
- -
-10.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
1
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
-52.11
-48.13
-93.38
- -
-268.56
2013
-48.61
-84.88
-59.19
- -
-153.67
2014
-54.19
-52.39
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
Peter G. Savas
Full Time Employees
3
Sector
Healthcare
Industry
Biotechnology
Address
275 Grove Street Auburndale MA United States of America 02466
IPO Date
Dec 22, 1994
Website
alseres.com
Similar Companies
Aptose Biosciences Inc. (APS.TO)
2cureX AB (publ) (2CUREX.ST)
EZZ Life Science Holdings Limited (EZZ.AX)
NewAmsterdam Pharma Company N.V. (NAMSW)
Arbutus Biopharma Corporation (ABUS)
Poxel S.A. (PXXLF)
Business
Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) develops diagnostic and therapeutic products primarily for central nervous system (CNS) disorders, including Parkinson’s disease, dementia, spinal cord injury, and stroke; its lead product candidate is Altropane, a molecular imaging agent employing iodine-123 radiolabeled [123I]-E-IACFT for aiding in the diagnosis of Parkinsonian syndromes and differentiating them from essential tremor or other movement disorders. The company advances regenerative therapeutics such as Cethrin, a recombinant-protein-based drug to promote nerve repair post-acute spinal cord injury which showed positive interim Phase I/IIa results, alongside preclinical candidates including Inosine for spinal cord injury and stroke treatment, Oncomodulin for ocular injury and disease, and programs targeting bone repair; it maintains research collaborations with Harvard Medical School and Children's Hospital Boston. Founded in 1972 and headquartered in Auburndale, Massachusetts, Alseres operates principally in the United States within the biotechnology sector, targeting neurologists, movement disorder specialists, and patients with CNS conditions through partnerships for product development and commercialization. The company, formerly Boston Life Sciences, Inc., changed its name to Alseres Pharmaceuticals, Inc. in June 2007 to reflect its strategic focus on biopharmaceuticals for CNS disorders, with shares trading under ALSE since June 11, 2007; it previously licensed worldwide rights to Altropane to Navidea Biopharmaceuticals and received funding including $34.4 million from investors such as Highbridge Capital Management and Ingalls & Snyder, though no major acquisitions, new product launches, or operational shifts have occurred in the last 1-2 years amid a dormant pipeline status.

Company News

MCPAPIChat

  • defenseworld.net

    Financial Contrast: Alseres Pharmaceuticals (OTCMKTS:ALSE) vs. Relmada Therapeutics (NASDAQ:RLMD)